CD274 and cancer: Targeting immune checkpoints can provide new insights for the treatment of cancer, and immune checkpoint inhibitors, such as atezolizumab and nab-paclitaxel, have been approved for the first-line therapy of PD-L1–positive metastatic triple-negative BC [63].